In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Tim Clay sits down with Australian oncology luminaries Prof Ben Solomon and A/Prof Malinda Itchins to discuss the rapidly evolving landscape of Anaplastic Lymphoma Kinase (ALK) positive lung cancer. Since its discovery in 2007, treatment for this subset of non-small cell lung cancer (NSCLC) has advanced through four generations of inhibitors, significantly improving survival outcomes for the 400–500 Australians diagnosed annually.
In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Tim Clay sits down with Australian oncology luminaries Prof Ben Solomon and A/Prof Malinda Itchins to discuss the rapidly evolving landscape of Anaplastic Lymphoma Kinase (ALK) positive lung cancer. Since its discovery in 2007, treatment for this subset of non-small cell lung cancer (NSCLC) has advanced through four generations of inhibitors, significantly improving survival outcomes for the 400–500 Australians diagnosed annually.
(00:00) Welcome and Acknowledgement
(00:43) Meet the Expert Guests
(01:40) ALK History and Breakthroughs
(03:48) Who Gets ALK Lung Cancer
(04:57) Workup and Staging Essentials
(05:54) Patterns of Spread and Clots
(07:24) Second Generation TKIs Standard
(09:03) Long Term Toxicities
(11:07) Progression Assessment and LAT
(12:50) Lorlatinib After Progression
(15:46) Lorlatinib First Line Crown Data
(17:11) Choosing and Dosing Lorlatinib
(20:55) Managing Lorlatinib Side Effects
(22:29) Predicting Response and Follow Up
(29:30) Next Generation Inhibitors NAL
(32:04) Early Stage and Adjuvant TKIs
(36:32) Beyond TKIs Chemo and ADCs
(39:30) Patient Support and Closing